From ImmunoToxins to ImmunoRNases

Journal: Current Pharmaceutical Biotechnology
Volume: 9 Issue: 3 Year: 2008 Page: 210-214
Author(s): Claudia De Lorenzo, Giuseppe DAlessio

Ribonucleases and ImmunoRNases as Anticancer Drugs

Journal: Current Pharmaceutical Design
Volume: 15 Issue: 2 Year: 2009 Page: 2665-2675
Author(s): S. M. Rybak, M. A.E. Arndt, T. Schirrmann, S. Dubel, J. Krauss

Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy

Journal: Current Pharmaceutical Biotechnology
Volume: 9 Issue: 3 Year: 2008 Page: 231-234
Author(s): Jurgen Krauss, Michaela A.E. Arndt, Stefan Dubel, Susanna M. Rybak

Modifications of Ribonucleases in Order to Enhance Cytotoxicity in Anticancer Therapy

Journal: Current Cancer Drug Targets
Volume: 22 Issue: 5 Year: 2022 Page: 373-387
Author(s):

Journal: Current Pharmaceutical Design
Volume: 15 Issue: 2 Year: 2009 Page: 2650-2651
Author(s): Stefan Barth

Editorial [Hot Topic: The Therapeutic Potential of Ribonucleases (Guest Editor: Urich Arnold) ]

Journal: Current Pharmaceutical Biotechnology
Volume: 9 Issue: 3 Year: 2008 Page: 134-134
Author(s): Ulrich Arnold

Anti-HER2 Cancer Therapy and Cardiotoxicity

Journal: Current Pharmaceutical Design
Volume: 20 Issue: 3 Year: 2014 Page: 4911-4919
Author(s): Tania Babar, Christopher Blomberg, Eileen Hoffner, Xinhua Yan

Physiological and Molecular Role of Ranpirnase on Cancer Treatment

Journal: Current Cancer Therapy Reviews
Volume: 6 Issue: 1 Year: 2010 Page: 26-33
Author(s): Intae Lee, Daehong Kim, Jihean Lee, Kuslima Shogen

rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine

Journal: Current Topics in Medicinal Chemistry
Volume: 17 Issue: 13 Year: 2017 Page: 1529-1541
Author(s): Ayse Goksu Kaya-Ozsan,Ayse Filiz Oner

Can Enzyme Engineering Benefit from the Modulation of Protein Motions? Lessons Learned from NMR Relaxation Dispersion Experiments

Journal: Protein & Peptide Letters
Volume: 18 Issue: 4 Year: 2011 Page: 336-343
Author(s): Nicolas Doucet